LMNTIC Biotech develops liquid biopsy technology to isolate rare tumor cells in blood LMNTIC Biotech pioneers novel ...

Global Refractory Follicular Lymphoma Diagnostics Market Projected to Reach USD 464.47 Million by 2029 Refractory Follicular ...

In a study involving 43 MBC patients, the liquid biopsy test reclassified three out of five patients who were initially deemed HER2-negative by tissue biopsy as HER2-positive. This discovery ...

The prevalence of cancer is escalating at an alarming rate globally, underscoring the need for robust diagnostic solutions. Factors such as growing awareness, supportive government initiatives, and ...

Pharus Diagnostics LLC. (PharusDx), an innovator in non-invasive diagnostic tests, today announced a significant step forward ...

Dong-A ST secures European approval for autoimmune treatment Immuldosa Dong-A ST gains EU clearance for its innovative ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutionsLOS ANGELES, ...

This past year, the role of ctDNA testing has expanded to guide treatment decisions for providers and patients with cancer.

Guardant Health (GH) announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the ...

Luis E. Raez, MD, discusses the current liquid biopsy options for patients with lung cancer through assessing circulating tumor DNA. Luis E. Raez, MD, medical director and chief scientific officer at ...